Cargando…

SARS-CoV-2: the many pros of targeting PLpro

Detalles Bibliográficos
Autores principales:	McClain, Christopher B., Vabret, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537779/ https://www.ncbi.nlm.nih.gov/pubmed/33024071 http://dx.doi.org/10.1038/s41392-020-00335-z

Ejemplares similares

Inhibitors of SARS-CoV-2 PLpro
por: Calleja, Dale J., et al.
Publicado: (2022)

Virtual Issue on SARS-CoV-2: Evolution of a Pandemic
por: McGrath, Casey
Publicado: (2023)

Super(antigen) target for SARS-CoV-2
por: Brown, Matthew, et al.
Publicado: (2021)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
por: Klemm, Theresa, et al.
Publicado: (2020)

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro
por: Swaim, Caleb D., et al.
Publicado: (2021)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

Antigen‐dependent multistep differentiation of T follicular helper cells and its role in SARS‐CoV‐2 infection and vaccination
por: Baumjohann, Dirk, et al.
Publicado: (2021)

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
por: Narayanan, Anoop, et al.
Publicado: (2022)

Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
por: Latorre, Daniela
Publicado: (2022)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

SARS-CoV-2 sensory loss
por: York, Ashley
Publicado: (2022)

Sewer biofilms and SARS-CoV-2
por: Du Toit, Andrea
Publicado: (2023)

SURFing SARS-CoV-2 inhibition
por: Taglialegna, Agustina
Publicado: (2023)

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities
por: Swaim, Caleb D., et al.
Publicado: (2020)

High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
por: Zhao, Yao, et al.
Publicado: (2021)

Evaluating Stability and Activity of SARS-CoV-2 PLpro for High-throughput Screening of Inhibitors
por: Arya, Rimanshee, et al.
Publicado: (2021)

Phytocompounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro through computational studies
por: Rudrapal, Mithun, et al.
Publicado: (2022)

Genetically Encoded Fluorescent Sensors for SARS-CoV-2 Papain-like Protease PLpro
por: Sokolinskaya, Elena L., et al.
Publicado: (2022)

Identification and characterization of aurintricarboxylic acid as a potential inhibitor of SARS-CoV-2 PLpro
por: Arya, Rimanshee, et al.
Publicado: (2023)

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach
por: Li, Jing, et al.
Publicado: (2020)

SARS-CoV-2 nanobodies 2.0
por: Labroussaa, Fabien, et al.
Publicado: (2021)

Pharmacotherapeutic Potential of Natural Products to Target the SARS-CoV-2 PLpro Using Molecular Screening and Simulation Approaches
por: Sayaf, Abrar Mohammad, et al.
Publicado: (2023)

A two‐step infection model: From SARS‐CoV‐2 entry and trafficking to egress and spread
por: You, Liting, et al.
Publicado: (2023)

A CNS gateway for SARS-CoV-2
por: Yates, Darran
Publicado: (2021)

SARS-CoV-2 detected in olfactory neurons
por: Lemprière, Sarah
Publicado: (2021)

Cellular basis for SARS-CoV-2 infection
por: Baumann, Kim
Publicado: (2020)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

Effects of mutations on SARS-CoV-2 fitness
por: Chirigati, Fernando
Publicado: (2022)

SARS-CoV-2 rewires host chromatin
por: Du Toit, Andrea
Publicado: (2023)

Landscapes of SARS-CoV-2-reactive CD8(+) T cells: heterogeneity of host immune responses against SARS-CoV-2
por: Koh, June-Young, et al.
Publicado: (2021)

SARS-CoV-2 spike protein: flexibility as a new target for fighting infection
por: Pierri, Ciro Leonardo
Publicado: (2020)

SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target
por: Giovannoni, Federico, et al.
Publicado: (2020)

Identification of Doxorubicin as Repurposing Inhibitory Drug for MERS-CoV PLpro
por: Alaofi, Ahmed L., et al.
Publicado: (2022)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

TMPRSS2, a novel host-directed drug target against SARS-CoV-2
por: Keller, Christian, et al.
Publicado: (2022)

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research
por: Häfner, Sophia Julia
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n6rkevb2bpj7c7i00003ti185t